Technical Articles

Adeno-associated virus (AAV) vector gene therapy has become a transformative approach for treating monogenic diseases, including hemophilia, spinal muscular atrophy, and hereditary retinal diseases. Its excellent safety, low immunogenicity, and ability to mediate long-term transgenic expression make it a leading platform in this field.